ストックスクリーナーアプリを入手
71.93
0.75%
-0.54
アフターアワーズ：
72.28
0.35
+0.49%
前日終値:
$72.47
開ける：
$72.87
24時間の取引高:
950.11K
Relative Volume:
0.51
時価総額：
$13.86B
収益：
$4.08B
当期純損益:
$32.48M
株価収益率:
513.79
EPS:
0.14
ネットキャッシュフロー:
$16.80M
1週間 パフォーマンス:
+1.97%
1か月 パフォーマンス:
+3.65%
6か月 パフォーマンス:
+10.15%
1年 パフォーマンス:
+17.00%
1日の値動き範囲:
$71.85
$73.00
1週間の範囲:
$69.65
$73.83
52週間の値動き範囲:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
71.93 | 13.86B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Incyte Gains 15.3% In A Year: Is There Room For Further Growth? - Barchart
Short Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1% - MarketBeat
INCY (Incyte) GF Value Rank : 8 (As of Jan. 20, 2025) - GuruFocus.com
Hennion & Walsh Asset Management Inc. Purchases 11,120 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
What You Need To Know Ahead Of Incyte's Earnings Release - Barchart
Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug - Law360
Contravisory Investment Management Inc. Has $750,000 Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CHURCHILL MANAGEMENT Corp Has $12.36 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Claro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
JP Morgan 2025: Incyte expects period of ‘defining catalysts’ - Yahoo Finance
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D - Barchart
Incyte's SWOT analysis: navigating patent cliff with promising pipeline - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
DPP-led Effort For Incyte Leads To Deal Of The Year Honors - Town Square Delaware LIVE
Incyte's (INCY) "Market Perform" Rating Reiterated at JMP Securities - MarketBeat
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline - Benzinga
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised - openPR
Pallas Capital Advisors LLC Makes New $1.01 Million Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? - MSN
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.29 - MarketBeat
Incyte: Multiple Drug Launches Bode Well For Future Growth - Seeking Alpha
Incyte (NASDAQ:INCY) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Incyte Corporation (INCY) Announces Executive Leadership Change - GuruFocus.com
Incyte Announces Retirement of Executive VP Barry Flannelly - TipRanks
JPMorgan Chase & Co. Reduces Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 - BioSpace
Incyte (MEX:INCY) Earnings Yield % : 0.09% (As of Jan. 08, 2025) - GuruFocus.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
CWA Asset Management Group LLC Acquires Shares of 27,984 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Has $9.40 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CDK2/cyclin E1 inhibitors disclosed in Incyte patent - BioWorld Online
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Principal Financial Group Inc. Has $14.59 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Tuesday, still underperforms market - MarketWatch
Is Incyte Stock Outperforming The Dow? - Barchart
Is Incyte Stock Outperforming the Dow? - Inkl
Franklin Resources Inc. Sells 50,188 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Sanctuary Advisors LLC Has $1.51 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
The Analyst Verdict: Incyte In The Eyes Of 15 Experts - Benzinga
Wells Fargo & Company Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com India
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
Incyte Corp (INCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Tray Thomas | Principal Accounting Officer |
Dec 16 '24 |
Sale |
69.31 |
650 |
45,052 |
23,312 |
4.62%
0.65%
大文字化:
|
ボリューム (24 時間):